Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 11/20 | 0.67 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.54 |
| ▸ | SMO | Q99835 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269604 | 0.87 | ACLY (0.69) | ACLYSUCNR1GRIK1SMODHODH | |
| SCHEMBL28925309 | 0.87 | ACLY (0.64) | ACLYSUCNR1GRIK1DHODHMEN1 | |
| SCHEMBL1316036 | 0.85 | ACLY (0.63) | ACLYSUCNR1GRIK1SMODHODH | |
| SCHEMBL2271570 | 0.83 | ACLY (0.60) | ACLYSUCNR1GRIK1DHODHMEN1 | |
| SCHEMBL2277921 | 0.83 | ACLY (0.49) | ACLYSUCNR1SMOMEN1NPC1 | |
| SCHEMBL2270596 | 0.82 | ACLY (0.70) | ACLYSUCNR1GRIK1SERPINE1MEN1 | |
| SCHEMBL2275720 | 0.81 | SUCNR1 (0.73) | ACLYSUCNR1GRIK1SERPINE1DHODH | |
| SCHEMBL2274563 | 0.81 | ACLY (0.81) | ACLYSUCNR1GRIK1SERPINE1SLC16A3 | |
| SCHEMBL2274511 | 0.81 | ACLY (0.72) | ACLYSUCNR1SERPINE1SLC16A3DHODH | |
| SCHEMBL2270222 | 0.81 | DHODH (0.77) | ACLYSUCNR1GRIK1SERPINE1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885SUCNR1 637/4885GRIK1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.